Estonia has one the highest number of new HIV diagnoses in the European Union, mainly among injecting drug users and heterosexuals. Little is known of HIV incidence, which is crucial for limiting the epidemic. Using a recent HIV infection testing algorithm (RITA) assay, we aimed to estimate HIV incidence in 2013.
Introduction
HIV infection is a major public health issue in former Soviet Union countries [1] , including Estonia. With a population of 1.312 million [2] , Estonia has experienced a rapidly expanding HIV epidemic from the year 2000 among young people who inject drugs (PWID), who are being infected with a rare HIV subtype, CRF06_cpx, and the highest diagnosis rate in the European Union of 105.3 per 100 000 population was reached in 2001 [3] [4] [5] . Several efforts have been undertaken by the Estonian government to contain the rapidly evolving epidemic, including a campaign to increase people's awareness of HIV infection, implementation of needle exchange programmes, and offering free testing for all pregnant women, prisoners, and those with behavioural risk factors, together with the availability of free-of-charge antiretroviral treatment for everyone [6, 7] . By 2013, the rate of reported new diagnoses had decreased and stabilized at 24.6/100 000 [4, 8] .
Case reporting of HIV infection is well established across Estonia and, since the first diagnosis of HIV infection in 1988, 9263 persons had been registered with the Estonian Health Board by the end of 2015. While injecting drug use was instrumental in the rise in new diagnoses, with 90% of cases in 2000 among PWID, the number of diagnoses attributable to heterosexual contact gradually increased, overtaking that of PWID in 2010, and representing 46% of all cases in 2014 [4] .
Although these figures are important measures of the epidemic, they do not necessarily reflect current transmission patterns. This is an important point as the ability to estimate the current HIV incidence is an essential public health monitoring tool indicating the characteristics of individuals at greatest risk, and guiding prevention and intervention strategies.
A number of serological tests have been developed which aim to differentiate recent from long-standing HIV infection [9] [10] [11] [12] [13] and allow the development of methods to estimate incidence using blood at a single time-point instead of time consuming cohort studies [14] [15] [16] .
While data on HIV incidence in Western countries exist [14, 17] , data for former Soviet Union countries, including Estonia, are limited [16] . We aimed to characterize the newly diagnosed HIV-positive population in Estonia using the recent HIV infection testing algorithm (RITA) to determine the proportion recently infected and estimate HIV incidence using previously published methodologies [14, 18] .
Methods

HIV testing in Estonia
An HIV test can be requested by any physician, including general practitioners, the cost of which is covered by health insurance, with an estimated 90% of the population being insured. Additionally, there are 23 counselling offices, where people can self-select for an HIV test free of charge, as well as occasional field-testing campaigns. Primary tests are performed in 24 local laboratories using enzyme-linked immunosorbent assay (ELISA) tests of various generations. All positive results are confirmed in a single HIV Reference Laboratory at West Tallinn Central Hospital using INNO-LIA â HIV I/II Score (Innogenetics N.V., Gent, Belgium), Bio-Rad's NEW LAV BLOT I (Bio-Rad Laboratories Inc., Hercules, CA, USA) and NEW LAV BLOT II (Bio-Rad Laboratories Inc.) tests, and reported to the Estonian Health Board. Screening for HIV antibodies is mandatory for blood and organ donors and for pregnant women at two timepoints during pregnancy, and is strongly recommended for patients with tuberculosis, as well as prison inmates. All HIV-positive individuals linked to care are invited to participate in the Estonian HIV database (E-HIV; www.
hiv.ut.ee) with signed informed consent being obtained as detailed elsewhere [8] .
Study population and design
We conducted a prospective study using existing country-wide HIV testing services. The study population consisted of all individuals aged ≥ 18 years with newly diagnosed HIV infection between 1 January 2013 and 31 December 2013. We linked test results from the Reference Laboratory to the Estonian Health Board database to obtain demographic data (sex, age, date of diagnosis, and reason for testing) using the unique Estonian national identification number (ID code) for all study subjects. Testing reasons were clinical signs suggestive of HIV infection, screening (antenatal or blood donors), indicator diagnosis (sexually transmitted disease or tuberculosis), indicator risk (injecting drug use, imprisonment or asymptomatic patient with known contact), other (preoperation or patient will) or not known. Additional data on possible date of seroconversion, self-reported risk factors, concomitant AIDS-defining condition(s) [19] , HIV-1 viral load and CD4 cell count within 6 months of diagnosis, as well as information on the use of combination antiretroviral therapy (cART), were extracted from the E-HIV database. Finally, the laboratory databases of four main hospitals À Tartu University Clinics, West-Tallinn Central Hospital, Narva Hospital, and Ida-Viru Central Hospital À were searched in April 2015 to identify previous negative HIV-1 antibody tests within 2 years of HIV diagnosis date, as well as HIV-1 viral load measurements within 6 months of diagnosis. All individuals with serum samples and available HIV viral load measurements were included in the final study population.
Laboratory methods
Left-over serum samples from newly diagnosed individuals in 2013 were obtained from the HIV Reference Laboratory of West Tallinn Central Hospital and tested for evidence of recent infection using the limiting antigen (LAg) avidity enzyme immunoassay (EIA) (Sedia tm HIV-1 LAg Avidity EIA; Sedia Biosciences Corporation, Portland, OR), according to the manufacturer's protocol [20] . The LAg avidity EIA is a single-well antibody aviditybased incidence assay, presenting multi-subtype recombinant HIV-1 glycoprotein 41 (gp41) antigen. The antibody avidity, the bond between antigen and antibody after using M citrate buffer as a dissociation agent, was measured as an optical density (OD) value. The initial test requires samples to be screened, with samples with an OD ≤ 2.0 tested in triplicate for confirmation and the median of three results being the final result. According to the 2013 protocol, an OD value < 1.5 is classified as recent infection, and the respective mean duration of an infection (recency period) is 130 days [95% confidence interval (CI) 118-142 days] [12, 20] .
Evaluations of the LAg avidity assay indicated that the assay performed poorly on specimens with a low or undetectable viral load and in persons receiving cART [13] . According to RITA, samples with a viral load < 1000 HIV-1 RNA copies/mL and individuals presenting with AIDS were reclassified as showing longstanding infection.
Statistical methods
An extrapolation method initially proposed by Karon et al. [18] and modified by Prejean et al. [14] was used to estimate HIV incidence. This method estimates the true number of recent infections within the population from the observed number of recent infections using the probability that a person will present for an HIV test and be classified as having recent infection using RITA. The true number of recent infections is estimated by dividing the observed number by the probability of testing and being classified as having a recent infection.
The observed number of recent infections equates to the number of HIV-positive individuals testing for HIV and being classified as having recent infection by RITA, after reclassifying LAg assay 'recent' samples with a viral load < 1000 copies/mL and individuals with an AIDSdefining illness as showing longstanding infection.
The probability that a person will present for an HIV test and be classified as recently infected using RITA is estimated for repeat testers and first-time testers separately. For repeat testers, the probability of testing and being classified as recently infected for an individual is the weighted sum of each possible date of seroconversion between the person's last negative and first positive test. For first-time testers, P is estimated by the weighted sum of the probability that a person tests within the assay's recency period and the probability that the test is performed before AIDS develops.
Incidence calculations have been thoroughly described elsewhere [16] . Rates were calculated by dividing the number of tests, the number of diagnoses or the estimated number of recent infections for the calendar year 2013 by the Estonian population denominator and multiplying by 100 000 [21] . Incidence rates were estimated for Estonia overall, and by age and sex using the general population estimates as denominators. The published estimates of the number of PWID were used to derive incidence estimates for this subgroup [21] .
Using a logistic regression model, we also examined factors associated with being recently infected with HIV. Variables included were: sex, age group, testing history, reason for test, and probable route of exposure. All CIs are at the 95% significance level.
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Results
Over the study period, 212 506 HIV tests were performed across Estonia, with 151 641 adults (aged ≥ 18 years) being tested. Of these, 69 115 subjects were referred by a physician or self-selected for a test and 82 526 individuals were tested as part of screening (63 972 blood donors and 18 554 women undergoing antenatal screening). There were 322 new adult HIV diagnoses, 286 among the nonscreened population (study population) and 36 among the screened population; the latter were excluded from further analysis.
The crude rate of new HIV diagnosis was 29.7 per 100 000 population (40.5 for men and 20.7 for women). A study flow diagram is presented in Figure 1 .
Characteristics of the study population
The median age of the study population at the time of HIV diagnosis was 33 years [interquartile range (IQR) 28-42 years] and men accounted for 65% of the sample. The majority of individuals lived in the capital Tallinn and were tested because of symptoms or high-risk behaviour (injecting drug use, imprisonment, or contact with a known HIV-positive individual). Two hundred and fortytwo individuals of 286 (85%) had not undergone testing within the last 2 years and were thus classified as firsttime testers (Table 1 ). The probability of testing and being classified as recently infected by RITA overall for repeat and first-time testers and demographic characteristics are shown in Table 2 .
The most common self-reported risk in the study population was sex between men and women (53%). Of the 63 individuals with unknown route of transmission, 46 (73%) were men. All individuals were ART-na€ ıve.
Recent HIV infection
The final study population consisted of 228 individuals after the additional exclusion of 29 individuals with insufficient serum for LAg testing and another 29 who did not have a viral load measurement within 6 months of diagnosis, as presented in Figure 1 . Of these, 86 (38%) were classified as recently infected according to the LAg assay. Four individuals out of 86 had a viral load < 1000 copies/mL and were therefore reclassified as having longstanding infection according to RITA, leaving 82 individuals (36%) classified as recently infected; 62 were first-time testers and 20 repeat testers ( Most of the 224 successfully sequenced samples were HIV-1 subtype CRF06_cpx (n = 180; 80%) with only five individuals with subtype B strains (2%).
HIV incidence estimates for the Estonian population
We estimated HIV incidence at 0.06% in 2013, corresponding to an estimated 642 new infections in that year (Table 3) . Of these, 12.8% (82 recent infections according to RITA among 642 estimated infections) were actually reported among the nonscreened population in the same year.
The HIV incidence was higher among younger age groups, being highest for age groups 18-29 (0.20%) and 30-39 years (0.22%). The incidence among men was higher than among women (0.08% and 0.05%, respectively) in the two above-mentioned age groups. We estimated the highest incidence among PWID at 1.48%.
Discussion
To the best of our knowledge, this is the first study to estimate HIV incidence covering the entire population of an Eastern European country and using a RITA in a population infected predominantly with a recombinant HIV-1 subtype.
We estimated the HIV incidence for Estonia during 2013 to be 0.06%; higher than the 29.7 per 100 000 population new diagnosis rate, and considerably higher than incidence estimates using the same methodology in Kiev, Ukraine (0.02%) [16] and the USA (0.019%) [14] . The diagnosis rate for Estonia is in accordance with published estimates from previous years, and remains one of the highest rates of new HIV diagnoses in Europe [23, 24] . The high incidence rate among PWID reported here of 1.48% is considerably higher than that reported previously by other investigators in the capital, Tallinn, of 0.02%, and probably reflects low success of preventive measures in this risk group [25] . IQR, interquartile range; PWID, people who inject drugs; MSM, men who have sex with men; RITA, recent infection testing algorithm. *Percentages in this column are percentages of the final study population. MSM, men who have sex with men; PWID, people who inject drugs. *The total number of MSM was too small (six individuals) for calculations. Estonia has a very similar HIV epidemic to Ukraine; both have the highest rates of new diagnoses in Europe, despite obvious economic differences, with gross national incomes per capita in 2014 of 3760 USD for Ukraine compared with 19 010 USD for Estonia [26] . National surveillance for both countries suggests that individuals at high risk of HIV infection are predominately PWID or heterosexuals, and not men who have sex with men (MSM). Interestingly, however, when persons self-reported their risk in Ukraine, 24% identified as MSM, who were also disproportionately affected by HIV infection [16] , in contrast to the proportion of 2% in our study in Estonia. In an epidemic predominantly in PWID and heterosexuals, one would expect similar HIV diagnosis rates among men and women. In our study, the HIV diagnosis rate among men was almost double that among women (40.5/100 000 versus 20.7/ 100 000, respectively). Still, men may be more likely than women to be drug injectors, as shown in Estonia in 2000, when more than 80% of HIV infections occurred in young men [4] . We also noted, however, that 73% of the 63 individuals in the unknown risk group were male, who were also more likely to be repeat testers compared to other risk group individuals, and previous studies have reported that MSM are more likely to be repeat testers [27, 28] . Taken together, these data may indicate that a significant proportion of men reporting risk factors other than MSM, as well as those with no reported risk, had acquired infection through sex with other men.
Although several efforts have been made to increase the number of people testing for HIV, for example through the countrywide HIV testing guidelines which were introduced in 2012 [29] , we found that only 15% of those testing in 2013, and 25% of those recently infected in that period, had previously tested for HIV, despite approximately 70 000 tests being performed that year, excluding screenings. We also found a high percentage of recent infections (36%) and that a small percentage (12.8%) of the estimated number of newly infected individuals were diagnosed, indicating that the at-risk population was being missed. Furthermore, we noted a high proportion of late presenters together with a median CD4 count at diagnosis in the final study population of 367 cells/lL. These results are similar to the late presentation rate of 38% and the median CD4 count at diagnosis of 368 cells/lL reported by the investigators of several Western European cohorts [30] . Given the high levels of viraemia, which characterize undiagnosed HIV infection [31] [32] [33] and a higher risk of onward transmission [34, 35] , as well as a higher risk of mortality and treatment failure for late presenters [36, 37] , there is an urgent need to promote HIV testing in the at-risk population to identify individuals close to the time of HIV infection and initiate cART.
Having a previous negative test was the only predictor for presenting with a recent infection, suggesting that these persons are aware of their risk factors, resulting in frequent tests. The risks of repeat testers need to be addressed. Surveillance of new diagnoses suggests that the number among PWID in Estonia has decreased, with the number of diagnoses attributable to heterosexual contact overtaking the number of diagnoses in PWID [4] . However, our estimates suggest that PWID remain an important population, incidence estimates among them being 24 times higher than the overall estimates.
The main strength of our study is the overall design of the national surveillance in Estonia, where individuals receive an ID code which allows data from multiple sources to be linked successfully. As data are directly reported from the Reference Laboratory to the Health Board, we believe that all new diagnoses in Estonia in 2013 were captured. We also made every effort to use data on previous testing history by interrogating laboratory and clinical databases rather than relying on selfreporting, which is a key element required to estimate incidence.
Some limitations should be noted. First, we acknowledge that some individuals may have been tested during testing campaigns or in 23 counselling offices across the country and their previous negative tests may, therefore, not have been recorded; this would have resulted in an underestimate of the proportion of repeat testers. Such individuals are likely to be few in number, however, and, in any case, would have been assigned to the recent infection category by the LAg assay. Secondly, not all individuals who were newly diagnosed had a viral load quantified at diagnosis. We were, however, able to link their records to viral load where the measurements were undertaken within 6 months of the HIV test; the median time from diagnosis was 10 days. Thirdly, we were unable to estimate incidence for any HIV risk group other than PWID, as general population figures are not available and/or the number testing positive whose HIV risk group was identified as MSM was very low. Finally, some uncertainties have been raised relating to the performance of the LAg assay in non-B HIV subtypes [38] , and the prevalent subtype in Estonia, CRF06_cpx, has not been included in assay development [39] . However, we found that most individuals with laboratory evidence of a negative HIV antibody test within 1 year prior to diagnosis were classified as recently infected, as were those diagnosed with seroconversion illness. Simulation of different assumptions in the incidence calculation was not conducted.
In conclusion, we demonstrate for the first time at a population level very high HIV-1 incidence in Estonia, especially among the young and PWID. There is clear indication of ongoing HIV transmission in all risk groups, with the possibility of undisclosed homosexuality in Estonia. All these findings need to be urgently addressed with improved implementation of preventive measures among appropriate risk groups and intensification of targeted HIV testing among the general population, especially in areas where the HIV epidemic is concentrated.
